Loading
Adipokines, Inflammation, and Metabolic Diseases · Journal article
Current Rheumatology Reports · August 8, 2026
Raises a question worth testing. It does not answer one.
This is a narrative review proposing that obesity-induced osteoarthritis constitutes a distinct metabolic phenotype driven by adipose-joint crosstalk through adipokine signalling, immune activation, and cellular heterogeneity. The authors synthesize mechanistic evidence from human and experimental studies to identify emerging therapeutic targets—including GLP-1 receptor agonists, anti-adipokine agents, and regenerative strategies—but present no primary efficacy data or controlled comparisons.
Narrative review. Persons with obesity-induced osteoarthritis; review also covers experimental model studies.
Obesity promotes adipose tissue hypertrophy, hypoxia, and inflammatory adipokine secretion that remodel systemic metabolism and alter joint-resident cell function Crosstalk between adipocytes, macrophages, fibroblasts, and chondrocytes sustains chronic low-grade inflammation, oxidative stress, and extracellular matrix degradation Single-cell analyses have revealed fibroblast and macrophage subsets that mediate depot-specific inflammatory circuits
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
This review reframes obesity-related osteoarthritis as a metabolic rather than purely mechanical disease, suggesting clinicians should consider systemic metabolic dysfunction and adipose inflammation when evaluating and treating obese patients with joint disease. However, the proposed therapeutic targets (GLP-1 agonists, anti-adipokine agents) require clinical validation before implementation.
A narrative review synthesizing mechanistic findings and proposing therapeutic opportunities in obesity-driven osteoarthritis, raising questions about adipose-joint pathways rather than testing them empirically.
As stated by the source record.
This review reframes obesity-related osteoarthritis as a metabolic rather than purely mechanical disease, suggesting clinicians should consider systemic metabolic dysfunction and adipose inflammation when evaluating and treating obese patients with joint disease. However, the proposed therapeutic targets (GLP-1 agonists, anti-adipokine agents) require clinical validation before implementation.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
PURPOSE OF REVIEW: Obesity-induced osteoarthritis (OA) is emerging as a distinct metabolic phenotype fundamentally different from mechanically driven OA. Current therapies largely target downstream joint damage and fail to address underlying adipose-joint pathological interactions. This review synthesises recent advances in understanding how systemic metabolic dysfunction, adipose tissue inflammation, and cellular heterogeneity revealed by single-cell analyses drive OA pathogenesis, and highlights emerging strategies targeting metabolic dysfunction and chronic inflammation. RECENT FINDINGS: We critically summarised human and experimental studies investigating the role of dysfunctional adipose depots, including visceral, subcutaneous, and infrapatellar fat, in joint degeneration. Mechanistic findings on adipokine signalling, immune activation, and metabolic stress were integrated with recent single-cell insights and therapeutic interventions addressing systemic metabolism and inflammation. Obesity promotes adipose tissue hypertrophy, hypoxia, and inflammatory adipokine secretion, which remodel systemic metabolism and alter the function of joint-resident cells. Crosstalk between adipocytes, macrophages, fibroblasts, and chondrocytes sustains chronic low-grade inflammation, oxidative stress, and extracellular matrix degradation. Single-cell analyses have revealed fibroblast and macrophage subsets that mediate depot-specific inflammatory circuits. Recent findings also point to metabolic modulators (GLP-1 receptor agonists), anti-adipokine agents, and regenerative strategies as promising interventions to modify disease progression. Obesity-induced OA arises from multi-level metabolic and inflammatory crosstalk between adipose and joint tissues. Deciphering adipose-joint crosstalk provides a foundation for precision therapies that address the upstream metabolic and inflammatory drivers of joint degeneration.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.